黄葵胶囊联合利拉鲁肽对早期糖尿病肾病患者的临床疗效
|
摘要
目的观察黄葵胶囊联合利拉鲁肽对早期糖尿病肾病患者的临床疗效。方法 60例患者随机分为黄葵胶囊联合胰岛素组和黄葵胶囊联合利拉鲁肽组,每组30例。治疗6个月后,比较两组BMI、FBG、HbA1c、UACR、UAER水平。结果治疗后,两组FBG、HbA1c、UACR、UAER水平均较治疗前显著下降(P<0.01);黄葵胶囊联合利拉鲁肽组UACR、UAER水平显著低于黄葵胶囊联合胰岛素组,FBG、HbA1c水平则恰好相反(P<0.05)。结论黄葵胶囊联合利拉鲁肽对早期糖尿病肾病患者有较好的临床疗效。
引文
[1]Yokoyama H,Araki S,Honjo J,et al.Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria[J].Diabetes Care,2013,36(10):3227-3233.
[2]Rossing K,Christensen P K,Hovind P,et al.Progression of nephropathy in type 2 diabetic patients[J].Kidey Int,2004,66(4):1596-1605.
[3]江思瑜,梁婵,吴晓光.利拉鲁肽对糖尿病肾病患者炎症因子影响的研究进展[J].中国药房,2017,28(2):280-283.
[4]夏小慧,陈娟,张日东,等.利拉鲁肽对糖尿病大鼠肾损伤的影响及机制[J].山东医药,2016,56(44):27-30.
[5]Imamura S,Hirai K,Hirai A.The glucagon-like peptide-1 receptor agonist,liraglutide,attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients[J].Tohoku J Exp Med,2013,231(1):57-61.
[6]王锋,范亚平,俞燕,等.黄葵胶囊对慢性肾脏病3期患者微炎症状态的影响[J].实用医学杂志,2012,28(10):1709-1710.
[7]张清德,曲忠森.黄葵胶囊对慢性肾脏病患者血清SOD、MDA、ET、NO及尿蛋白的影响[J].中国中西医结合肾病杂志,2010,11(6):544-545.
[8]邹洪斌,张立,杨立志.黄葵胶囊治疗糖尿病肾病的临床疗效观察[J].现代预防医学,2006,33(11):2197-2198.
[9]余江毅,熊宁宁,郭惠芳,等.黄蜀葵花醇提物治疗糖尿病肾病的临床观察[J].中国中西医结合杂志,1995,15(5):263-265.
[10]Ge J,Miao J J,Sun X Y,et al.Huangkui capsule,an extract from Abelmoschus manihot(L.)medic,improves diabetic nephropathy via activating peroxisome proliferator-activated receptor(PPAR)-α/γand attenuating endoplasmic reticulum stress in rats[J].J Ethnopharmacol,2016,189:238-249.
[11]赖先银,赵玉英,梁鸿.黄蜀葵花化学成分的研究[J].中国中药杂志,2006,31(19):1597-1600.
[12]Cai H D,Su S L,Qian D W,et al.Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids[J].J Ethnopharmacol,2017,206:152-159.
[13]Mao Z M,Shen S M,Wan Y G,et al.Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways,compared toα-lipoic acid[J].J Ethnopharmacol,2015,173:256-265.
[14]Retnakaran R,Kramer C K,Choi H,et al.Liraglutide and the preservation of pancreaticβ-cell function in early type 2 diabetes:the LIBRA trial[J].Diabetes Care,2014,37(12):3270-3278.
[15]Mann J F E,rsted D D,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes[J].N Engl J Med,2017,377:839-848.
[16]de Lucas M D G,Bueno B A,Sierra J O.Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease[J].Eur J Intern Med,2017,44:e28-e29.
[2]Rossing K,Christensen P K,Hovind P,et al.Progression of nephropathy in type 2 diabetic patients[J].Kidey Int,2004,66(4):1596-1605.
[3]江思瑜,梁婵,吴晓光.利拉鲁肽对糖尿病肾病患者炎症因子影响的研究进展[J].中国药房,2017,28(2):280-283.
[4]夏小慧,陈娟,张日东,等.利拉鲁肽对糖尿病大鼠肾损伤的影响及机制[J].山东医药,2016,56(44):27-30.
[5]Imamura S,Hirai K,Hirai A.The glucagon-like peptide-1 receptor agonist,liraglutide,attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients[J].Tohoku J Exp Med,2013,231(1):57-61.
[6]王锋,范亚平,俞燕,等.黄葵胶囊对慢性肾脏病3期患者微炎症状态的影响[J].实用医学杂志,2012,28(10):1709-1710.
[7]张清德,曲忠森.黄葵胶囊对慢性肾脏病患者血清SOD、MDA、ET、NO及尿蛋白的影响[J].中国中西医结合肾病杂志,2010,11(6):544-545.
[8]邹洪斌,张立,杨立志.黄葵胶囊治疗糖尿病肾病的临床疗效观察[J].现代预防医学,2006,33(11):2197-2198.
[9]余江毅,熊宁宁,郭惠芳,等.黄蜀葵花醇提物治疗糖尿病肾病的临床观察[J].中国中西医结合杂志,1995,15(5):263-265.
[10]Ge J,Miao J J,Sun X Y,et al.Huangkui capsule,an extract from Abelmoschus manihot(L.)medic,improves diabetic nephropathy via activating peroxisome proliferator-activated receptor(PPAR)-α/γand attenuating endoplasmic reticulum stress in rats[J].J Ethnopharmacol,2016,189:238-249.
[11]赖先银,赵玉英,梁鸿.黄蜀葵花化学成分的研究[J].中国中药杂志,2006,31(19):1597-1600.
[12]Cai H D,Su S L,Qian D W,et al.Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids[J].J Ethnopharmacol,2017,206:152-159.
[13]Mao Z M,Shen S M,Wan Y G,et al.Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways,compared toα-lipoic acid[J].J Ethnopharmacol,2015,173:256-265.
[14]Retnakaran R,Kramer C K,Choi H,et al.Liraglutide and the preservation of pancreaticβ-cell function in early type 2 diabetes:the LIBRA trial[J].Diabetes Care,2014,37(12):3270-3278.
[15]Mann J F E,rsted D D,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes[J].N Engl J Med,2017,377:839-848.
[16]de Lucas M D G,Bueno B A,Sierra J O.Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease[J].Eur J Intern Med,2017,44:e28-e29.